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The Dipole Potential Modifies the 
Clustering and Ligand Binding 
Affinity of ErbB Proteins and Their 
Signaling Efficiency
Tamás Kovács1, Gyula Batta1, Tímea Hajdu1, Ágnes Szabó1,2, Tímea Váradi1, Florina Zákány1, 
István Csomós1, János Szöllősi1,2 & Peter Nagy1
Although activation of the ErbB family of receptor tyrosine kinases (ErbB1-4) is driven by 
oligomerization mediated by intermolecular interactions between the extracellular, the kinase 
and the transmembrane domains, the transmembrane domain has been largely neglected in this 
regard. The largest contributor to the intramembrane electric field, the dipole potential, alters the 
conformation of transmembrane peptides, but its effect on ErbB proteins is unknown. Here, we show 
by Förster resonance energy transfer (FRET) and number and brightness (N&B) experiments that the 
epidermal growth factor (EGF)-induced increase in the homoassociation of ErbB1 and ErbB2 and their 
heteroassociation are augmented by increasing the dipole potential. These effects were even more 
pronounced for ErbB2 harboring an activating Val → Glu mutation in the transmembrane domain 
(NeuT). The signaling capacity of ErbB1 and ErbB2 was also correlated with the dipole potential. Since 
the dipole potential decreased the affinity of EGF to ErbB1, the augmented growth factor-induced 
effects at an elevated dipole potential were actually induced at lower receptor occupancy. We conclude 
that the dipole potential plays a permissive role in the clustering of ErbB receptors and that the effects 
of lipid rafts on ligand binding and receptor signaling can be partially attributed to the dipole potential.
ErbB proteins are known to a wide array of scientists ranging from cell biologists to clinical researchers1,2. The 
interest in this family of receptor tyrosine kinases stems from the fact that its members, ErbB1-4 (also known as 
HER1-4), are prototypes of dimerization-activated proteins, and they are involved in the pathogenesis of cancer3. 
Activated ErbB proteins turn on signaling via the MAPK and PI3K (phosphatidylinositol 3-kinase) pathways 
leading to proliferation, increased motility or differentiation depending on the context of the stimulation2. The 
fact that ErbB proteins are drugable targets led to the development of targeted cancer therapeutics4.
Clustering plays a key role in the activation of ErbB proteins. The dogma, formulated for ErbB1 (also known 
as epidermal growth factor (EGF) receptor), involves the ligand-induced dimerization of monomeric receptors 
as a result of a transition of the extracellular domain from a closed to an extended conformation in which the 
dimerization arm is exposed5. Several findings suggest that a process more complex than the one outlined above 
is involved in receptor activation. Binding of a single EGF molecule leads to the formation of an asymmetric 
dimer believed to form the structural basis of negative cooperativity in ligand binding6,7. Preformed ErbB1 dimers 
are also thought to exist8, although mainly at non-physiologically high expression levels9. Quantitative live cell 
imaging revealed that unliganded ErbB1 receptors form transient dimers10. Higher order clusters have also been 
identified for ErbB1-38,11,12.
In addition to the extracellular domain the transmembrane and the intracellular domains also play a role in 
the clustering of ErbB receptors. The structure of the autoinhibited conformation of the ErbB1 kinase domain 
resembles that of inactive cyclin-dependent kinases. Upon activation two kinase domains form an asymmetric 
dimer in which the “receiver” kinase is turned on by the “activator” kinase13. A similar sharing of tasks has also 
been indirectly shown for the kinase domains in ErbB heterodimers14.
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We have a much less clear view about the role of the transmembrane domain (TMD) in dimerization. 
Although the linkage between the extra- and intracellular domains provided by the transmembrane and jux-
tamembrane domains seems to be very flexible15,16, several lines of evidence suggest that the TMD does have a 
remarkable role in receptor activation. A Val→ Glu point mutation in the TMD of human ErbB2 (NeuT) or its rat 
homolog increases the formation of active ErbB2 homodimers17,18. (Although the designation Neu was originally 
used to describe an oncogene from nitrosoethylurea-induced rat neuroblastomas, it is nowadays widely used to 
refer to the human ErbB2/HER2 oncoprotein as well. All the protein or gene symbols in the paper refer to the 
human versions). Replacement of the same valine with isoleucine as a result of single nucleotide polymorphism 
leads to reduced risk of breast cancer19. It is believed that two terminal GXXXG motifs stabilize two different 
TMD dimers17. The two motifs are believed to differ regarding their role in stabilizing homo- and heterodimeric 
interactions between TMDs20. Homodimers of the TMDs of ErbB1 and ErbB2 and their heterodimers show 
the strongest tendency for association among the possible combinations of ErbB proteins21. The involvement of 
the TMD in receptor activation can be exploited for therapeutic purposes by oligopeptide sequences competi-
tively blocking receptor dimerization, activation and tumor growth22. A global model for the activation of ErbB1 
suggests that the TMD and the kinase domains have intrinsic dimerization and self-activation tendency, which 
is counteracted by the tethered conformation of the extracellular domain, by the formation of inactive kinase 
dimers and by interactions of the juxtamembrane segment with anionic lipids of the membrane23–27. This inhibi-
tory mechanism is relieved by ligand binding to the extracellular domain27.
The electric field in the membrane alters the conformation of the TMD28. Besides the transmembrane potential, 
whose magnitude is 50–100 mV, the dipole potential must also affect the TMD since its magnitude is several hun-
dred millivolts, and due to the steeper change in the potential the electric field generated by the dipole potential 
is 108–109 V/m as opposed to the much weaker (~2.5·107 V/m) electric field associated with the transmembrane 
potential28. The dipole potential is generated by the dipole moments of lipid carbonyl groups, cholesterol and the 
non-random orientation of water molecules on the surface of the membrane29,30. The dipole potential has been 
shown to alter transmembrane diffusion of charged molecules28, ligand binding31 and the structure and function 
of ion pumps32. Owing to the richness of lipid rafts in cholesterol the dipole potential is assumed to be larger in 
these microdomains than in the rest of the membrane33.
Although the dipole potential is expected to influence the conformation of the TMD of membrane proteins, 
its effect has not been tested on ErbB proteins. Here, we show that alterations in the dipole potential modify the 
clustering and signaling properties of ErbB1 and ErbB2, and conclude that the dipole potential plays a permissive 
role in the activation of these receptors.
Results
Binding of EGF is Significantly Inhibited by an Elevated Dipole Potential. Phloretin and 6-keto-
cholestanol were used to decrease and increase the dipole potential, respectively (see Supplementary Results and 
Fig. S1 for details of ratiometric measurement of the dipole potential). First, the binding affinity of fluorescent 
EGF to three different cell lines was determined and the analysis revealed that an elevated dipole potential sig-
nificantly reduced the affinity of EGF to ErbB1 (Table 1, Fig. S2). Incorporation of a fluorescent dye may alter 
the interaction of EGF with the dipole potential. In order to exclude the possibility that the observed inhibited 
binding of EGF at a high dipole potential was due to the presence of the fluorescent label, competitive binding 
experiments were carried out. The binding affinity of unlabeled EGF was reduced by a high dipole potential to 
a similar extent as for fluorescent EGF (Table 1, Fig. S2). Next, the binding of fluorescent EGF was tested under 
conditions used for stimulation experiments. The binding of fluorescent EGF was reduced by ~50% at an elevated 
dipole potential when growth factor labeling was performed either on ice or at 37 °C (Fig. 1 showing representa-
tive results for SKBR-3). These results are in agreement with predictions based on the binding curves. While the 
binding of EGF was significantly modified by the dipole potential, the expression of the receptor, ErbB1, was not 
modified as shown by the unaltered binding of an ErbB1-specific antibody (Fig. 1). Binding of EGF was restricted 
to the cell membrane in the experiment carried out on ice, while the growth factor was endocytosed and reached 
intracellular compartments at 37 °C. These experiments convincingly showed that the ligand binding ability of 
ErbB1 was significantly inhibited by an elevated dipole potential.
Treatment
SKBR-3 HeLa A431
non-competitive competitive non-competitive competitive non-competitive competitive
Kd (labeled) 
[nM] IC50 [nM] Ki [nM]
Kd (labeled) 
[nM] IC50 [nM] Ki [nM]
Kd (labeled) 
[nM] IC50 [nM] Ki [nM]
Pluronic F-127 0.37 ± 0.07 6.44 ± 0.94 0.44 ± 0.1 2.1 ± 0.12 13.9 ± 1.65 4.1 ± 0.31 0.99 ± 0.1 6.1 ± 0.8 1 ± 0.15
phloretin 0.29 ± 0.05 5.3 ± 0.5 0.3 ± 0.07 2.47 ± 0.2 11.8 ± 1.9 3.9 ± 0.27 0.98 ± 0.08 7 ± 0.7 1.15 ± 0.18
6-ketocholestanol 7.23* ± 0.37 15.9* ± 1.3 9.4* ± 1.02 18.6* ± 0.25 33.5* ± 3.9 26.4* ± 1.62 1.63* ± 0.21 10.6* ± 1 2.6* ± 0.33
Table 1.  Binding affinity of fluorescent and unlabeled EGF to ErbB1 at different dipole potentials. Control 
cells (Pluronic F-127) or those with an altered dipole potential (phloretin, 6-ketocholestanol) were incubated 
with a dilution series of fluorescent EGF and the Kd was determined by fitting the Hill equation to the measured 
data points (non-competitive). Alternatively, cells were incubated with a dilution series of unlabeled EGF in the 
presence of a constant concentration of fluorescent EGF. The IC50 was determined by fitting and the Ki values 
were calculated using the Kd values determined previously. The original curves are shown in Fig. S2 (*p < 0.05, 
compared to Pluronic F-127-treated control cells by ANOVA followed by Tukey’s HSD test).
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The Effect of the Dipole Potential on the Clustering of ErbB1 and ErbB2. Since transmembrane sig-
naling induced by EGF is preceded by clustering of ErbB receptors, we investigated whether alterations in the dipole 
potential have any effect on receptor oligomerization in quiescent or stimulated cells. According to flow cytometric 
FRET (Figs 2 and S3) and N&B (Figs 3 and S3) experiments the dipole potential exerted only minor effects on 
the homoassociation of ErbB1 and ErbB2 in non-stimulated cells with an increased homoclustering of ErbB1 at 
an elevated dipole potential being the only significant effect in N&B measurements. In accordance with previous 
results9 ErbB1 was mainly monomeric in unstimulated cells, since the molecular brightness of ErbB1-EGFP (0.07) 
was comparable to that of monomeric EGFP (0.06). On the other hand, ErbB2 formed clusters in quiescent cells 
judged from the almost threefold difference between the molecular brightness of ErbB2-mYFP (0.08) and that of 
monomeric mYFP (0.032). Homoclustering of the TMD mutant NeuT was significantly enhanced even in unstim-
ulated cells by an elevated dipole potential according to both FRET and N&B measurements (Fig. 4B,C). Although 
the homoclustering of transfected wild-type ErbB2 was also slightly increased by the dipole potential according to 
FRET measurements, this effect was less significant than that on NeuT (15% and 52% 6-ketocholestanol-induced 
relative increase in the FRET efficiency for wild-type ErbB2 and NeuT, respectively; p < 0.05).
In order to reveal the effect of the dipole potential on EGF-induced receptor clustering both the FRET and 
the molecular brightness values had to be normalized in order to eliminate variability in the values in unstimu-
lated cells. Contrary to resting cells, an elevated dipole potential significantly and systematically promoted the 
EGF-induced homoassociation of ErbB1 and ErbB2 according to FRET and N&B measurements (Figs 2A,B and 3). 
Although the phloretin-induced decrease in the dipole potential had a less predictable effect, the EGF-induced 
homoclustering of ErbB2 was significantly inhibited by phloretin (Figs 2B and 3B). The opposite behavior of 
ErbB1 and ErbB2 homoclusters in N&B measurements after EGF stimulation is in accordance with our previous 
results in which we showed that EGF induces ErbB1-2 heteroassociations by recruiting ErbB2 from large-scale 
ErbB2 homoclusters thereby decreasing the size of ErbB2 homo-oligomers9. An elevated dipole potential exerted 
an approximately 2-times larger effect on the EGF-induced homoclustering of NeuT as compared to that on 
wild-type ErbB2 according to FRET and N&B measurements since the relative, 6-ketocholestanol-induced 
change in the FRET values in EGF-stimulated samples were 19% and 40% for wild-type ErbB2 and NeuT, respec-
tively, and the 6-ketocholestanol-induced rise in the molecular brightness values were 13% and 33% under the 
same two conditions (Figs 3–4, p<0.05).
Since ErbB2 is the preferred heterodimerization partner of EGF-activated ErbB134, the investigation of the 
effect of the dipole potential on clusters of ErbB1 and ErbB2 would be incomplete without measuring their 
heteroassociation. According to flow cytometric FRET measurements the dipole potential did not have any 
effect on the heteroclustering of ErbB1 with ErbB2 in quiescent cells, while the EGF-induced increase in the 
interaction of the two receptors was significantly higher in cells in which the dipole potential was elevated by 
Figure 1. The effect of the dipole potential on the cell surface expression and ligand binding of ErbB1. 
Starved SKBR-3 cells were treated with phloretin or 6-ketocholestanol in the presence of Pluronic F127 followed 
by incubating them with 100 ng/ml (~16 nM) tetramethylrhodamine-conjugated EGF at 37 °C for 5 min, on 
ice for 30 min or with AlexaFluor546-Ab11 against ErbB1 on ice for 30 min. Fluorescence intensities were 
background-corrected and normalized to the intensity of control samples treated with Pluronic F127 only. The 
mean of three independent flow cytometric measurements (± standard error of the mean) are shown in the 
figures. Asterisks indicate significant differences compared to the control samples (p < 0.05, ANOVA followed 
by Tukey’s HSD test).
www.nature.com/scientificreports/
4Scientific RepoRts | 6:35850 | DOI: 10.1038/srep35850
6-ketocholestanol (Fig. 2C). We concluded that the homo- and heteroassociations of ErbB1 and ErbB2, especially 
in ligand-stimulated cells, show a positive correlation with the dipole potential.
Dipole potential-induced changes in EGF-induced signaling. Ligand-induced clustering of ErbB 
receptors leads to phosphorylation of tyrosine residues in the receptors and spreading of the tyrosine phospho-
rylation signal. In order to test whether the dipole potential-related changes observed in the clustering of ErbB1 
Figure 2. The effect of the dipole potential on the homo- and heteroassociations of ErbB1 and ErbB2. 
ErbB1 homoassociation (A), ErbB2 homoassociation (B), and the heteroassociation of ErbB1 and ErbB2  
(C) in control, phloretin- and 6-ketocholestanol-treated cells were measured by flow cytometric FRET. In 
each measurement, the calculated mean FRET efficiencies were normalized to the mean FRET efficiencies 
observed in samples treated with Pluronic F127. The numbers above the columns represent the unnormalized 
mean FRET efficiency (± standard error of the mean) of the serum-starved control sample. The columns and 
the error bars represent the means and their standard errors, respectively, determined from four independent 
measurements. Two-way ANOVA was performed and pairwise comparisons were carried out by Tukey’s HSD 
test. Asterisks indicate significant differences compared to the control sample of the respective treatment group 
(p < 0.05, ANOVA followed by Tukey’s HSD test). Representative FRET histograms used for calculating data 
presented in this figure are shown in Fig. S3.
Figure 3. The effect of the dipole potential on the homoassociation of ErbB1 and ErbB2 measured by N&B 
analysis. The homoassociation of ErbB1 (A) and ErbB2 (B) were determined in F1-4 cells stably expressing 
ErbB1-EGFP and HeLa cells transfected with ErbB2-mYFP, respectively. The observed molecular brightness 
was normalized to the mean molecular brightness of the starved sample treated with Pluronic F127. The 
normalized molecular brightness values of ErbB1-EGFP and ErbB2-mYFP (mean ± standard error of the 
mean), determined from six independent experiments, are shown in the graph. The numbers above the columns 
represent the unnormalized molecular brightness (± standard error of the mean) of the serum-starved control 
sample. The values in parentheses are the molecular brightness values of monomeric fluorophores. Asterisks 
indicate a significant difference compared to the control sample of the respective treatment group (p < 0.05, 
ANOVA followed by Tukey’s HSD test). Representative brightness histograms used for calculating data 
presented in this figure are shown in Fig. S3.
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and ErbB2 are mirrored in their signaling the level of tyrosine phosphorylation was determined in quiescent and 
EGF-stimulated cells using antibodies against phosphotyrosine, ErbB1 phosphorylated at Tyr1068 and ErbB2 
phosphorylated at Tyr1248. Similar to the FRET and N&B experiments normalization of the tyrosine phospho-
rylation to unstimulated control cells eliminated the variability in the baseline level of activation. Alteration of 
the dipole potential did not modify the low level of tyrosine phosphorylation in unstimulated cells, while the 
EGF-induced response was correlated with the dipole potential (Fig. 5). Similar to the FRET and N&B measure-
ments the effect of the dipole potential on NeuT was more pronounced than on wild-type ErbB2. We concluded 
that the growth factor-induced tyrosine phosphorylation response of cells was also significantly modified by the 
dipole potential.
Correlation between the activation of ErbB2, its raft localization and the dipole potential. 
Since the dipole potential is assumed to be different in lipid rafts than in the rest of the membrane, we expected 
some sort of correlation between the activation state of ErbB2, its raft localization and the dipole potential. Cells 
treated with 6-ketocholestanol to increase their dipole potential were compared to control cells. The tyrosine 
phosphorylation of ErbB2 was normalized to its expression level and separately evaluated in raft and non-raft 
regions of the cell membrane corresponding to areas with high and low CTX labeling, respectively. In cells with 
an unmodified dipole potential there was no difference between the normalized tyrosine phosphorylation of 
ErbB2 inside and outside lipid rafts (Fig. 6A). Increasing the dipole potential enhanced the activation state of 
ErbB2 and it did so more pronouncedly outside lipid raft regions. EGF stimulation led to ErbB2 tyrosine phos-
phorylation both inside and outside lipid rafts in cells with an unmodified dipole potential and the increase was 
more pronounced in regions outside lipid rafts. EGF stimulation in cells with an increased dipole potential did 
not increase the normalized tyrosine phosphorylation of ErbB2 further. Differences between the effects of EGF 
stimulation presented in Figs 5 and 6 may be related to the fact that trypsinized cells were stimulated in flow cyto-
metric experiments (Fig. 5) while attached cells were investigated in the measurements presented in Fig. 6, and 
trypsinization alone can lead to stimulation of signaling pathways and diminish growth factor-induced effects 
(Fig. S4). The results suggest that 6-ketocholestanol-induced increase in the dipole potential affects ErbB2 tyros-
ine phosphorylation more significantly outside lipid rafts. The fact that EGF stimulation led to a larger rise in 
ErbB2 tyrosine phosphorylation outside lipid rafts suggests that the growth factor either preferentially activates 
ErbB2 outside lipid rafts or activated ErbB2 migrates out of lipid rafts. This assumption was corroborated by a sig-
nificant decrease in the correlation coefficient between phosphorylated ErbB2 and CTX staining upon EGF and 
6-ketocholestanol treatments (Fig. 6B) while the effects on the correlation between ErbB2 and CTX intensities 
were less substantial. In conclusion, the results suggest that activation of ErbB2 by either EGF or increased dipole 
potential preferentially takes place outside lipid rafts.
Discussion
In the current manuscript we showed that the dipole potential is significantly correlated with the clustering 
of ErbB1 and ErbB2. The effect was systematically observed in EGF-stimulated cells, whereas changes in the 
dipole potential did not exert substantial effects on ErbB1 and ErbB2 in unstimulated cells. The increased growth 
factor-induced association of ErbB proteins at an elevated dipole potential was correlated with enhanced signaling 
which is in line with receptor dimers or clusters being the active signaling units. However, the fact that increased 
Figure 4. The effect of the dipole potential on the homoclustering of NeuT. HeLa cells were transfected 
with wild-type ErbB2 (A), with NeuT (B) or with NeuT fused with mYFP (C) and their homoclustering was 
measured by flow cytometric FRET (A,B) or N&B analysis (C). The calculated molecular brightness and 
FRET values were normalized to the mean of the starved sample treated with Pluronic F127. The normalized 
molecular brightness or FRET values (mean ± standard error of the mean), determined from six independent 
experiments, are shown in the graph. The numbers above the columns on the left represent the unnormalized 
molecular brightness or FRET values (± standard error of the mean) of the serum-starved control sample. 
The value in parentheses is the molecular brightness value of a monomeric fluorophore. Asterisks indicate a 
significant difference compared to the control sample of the respective treatment group (p < 0.05, ANOVA 
followed by Tukey’s HSD test).
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signaling at an elevated dipole potential was correlated with reduction of ligand binding was unexpected. If this 
suppressed ligand binding at an elevated dipole potential is taken into account, the dipole potential-induced aug-
mentation of the EGF effect is even larger since a lower amount of bound ligand brings about the larger changes in 
the clustering and phosphorylation of ErbB1 and ErbB2. This apparent contradiction can be resolved by assuming 
that the increase of the dipole potential favors the active conformation of the transmembrane domain dimers 
which eventually induces conformational transitions in the extra- and intracellular domains as well resembling 
or identical to those induced by growth factor binding. In light of the above reasoning a lower amount of bound 
ligand at an elevated dipole potential can induce stronger signaling since both growth factor binding and the 
dipole potential induce the conformational changes leading to receptor activation.
The reduced affinity of EGF binding is also in line with the dipole potential-induced conformational change 
in the extracellular domain. It has been shown that the ligand binding site is structurally restrained in ErbB1 
dimers6,7. Consequently, ligand independent, dipole potential-driven formation of receptor dimers leads to gen-
eration of compressed ligand binding pockets and reduced affinity.
Lipid rafts regulate EGF-mediated signaling since both ErbB135 and ErbB236,37 have been shown to be raft 
resident. Lipid rafts are presumed to play a bipartite role in the clustering and signaling of ErbB proteins. They 
inhibit ligand binding38–40, but potentiate growth factor-induced signaling at the same time35–37. Since the dipole 
potential is stronger in lipid rafts than in non-raft domains33, it must not be overlooked when interpreting 
raft-dependent effects on receptor function. Indeed, our results show that the dipole potential inhibits ligand 
binding and potentiates EGF-mediated signaling which exactly mirrors the bipartite effect of lipid rafts. The 
magnitude of increase in the dipole potential induced by 6-ketocholestanol treatment must be higher in non-raft 
domains since the dipole potential-induced activation of ErbB2 was more pronounced outside lipid rafts.
Figure 5. The effect of the dipole potential on EGF-induced tyrosine phosphorylation. General tyrosine 
phosphorylation was determined by PY99 (A), whereas ErbB1 phosphorylation at Tyr1068 and ErbB2 
phosphorylation at Tyr1248 were measured by anti-pEGFR (B), and Ab18 antibodies (C), respectively. The 
mean fluorescence intensities of control and EGF-treated samples labeled with AlexaFluor546-goat-anti-mouse 
antibodies were normalized to the means of samples treated with Pluronic F127. The means (± standard error 
of the mean) of four independent measurements are shown. Two-way ANOVA was performed and pairwise 
comparisons were carried out by Tukey’s HSD test. Asterisks indicate significant differences compared to the 
control sample of the respective treatment group (p < 0.05).
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We considered six possible models for explaining the phenomenon that the dipole potential only affects 
ligand-induced clusters without influencing constitutive ones.
1. The dipole potential may only exert a permissive effect on clustering which is not strong enough for alter-
ing the weak and transient constitutive dimers and oligomers.
2. It has been suggested that constitutive dimers or oligomers are generated by corralling or confinement by 
the cytoskeleton10, while actively signaling receptor clusters are held together by protein-protein interac-
tions41,42. Since it is unlikely that the membrane dipole potential affects corralling and confinement, it only 
exerts effects on ligand-induced clusters.
3. Parallel alpha helices, present in dimers of single-pass transmembrane proteins, exert a repulsive electro-
static force on each other43. The N-terminal and C-terminal dimerization motifs are thought to contrib-
ute to the stabilization of dimers of the TMD with the N-terminal one implicated in stabilizing active 
dimers17,24,27. Although a lot of controversy surrounds the magnitude of the “macroscopic” net dipole 
moment equivalent to the α helical TMD44, it is reasonable to approximate it by placing half unit negative 
and positive charges near the C- and N-terminus, respectively45. According to a semiquantitative model 
presented in Fig. S5 the magnitude of the membrane dipole potential is similar to the electric potential 
leading to the repulsion of the helix termini. The membrane dipole potential counterbalances this repulsion 
at the N-termini leading to the stabilization of interaction between the N-terminal dimerization motifs 
thought to be responsible for active dimers. On the other hand, the membrane dipole potential does not 
have such an effect on the C-terminal dimerization motifs. Since the dimerization motifs have been shown 
to interact specifically with each other, the dipole potential only alters the strength of their interaction. 
The larger effect of the dipole potential on NeuT as compared to wild-type ErbB2 is in agreement with the 
above reasoning since the Val→ Glu mutation favors interactions between the N-terminal dimerization 
motifs stabilizing active dimers17.
4. Interactions of the juxtamembrane segment with negatively charged lipids in the inner leaflet of the plasma 
membrane have been shown to prevent the formation of active receptor dimers, while dimerization of 
the juxtamembrane domains orient the kinase domain to adopt their active conformation23–25. Since the 
juxtamembrane domain is embedded in the hydrophobic core of the membrane24, the positively charged 
lysine residues in the JM-A segment may be repelled by the positive lobe of the dipole potential. In this way, 
an increased dipole potential may destabilize the membrane embedding of the JM-A segment favoring the 
formation of juxtamembrane domain dimers in which the positively charged lysine residues do not pene-
trate the membrane.
5. Exposure of the TMD helix termini to water decreases their dipole moment and repulsion44. Consequently, 
if the dipole potential decreased membrane thickness, less repulsion between TMDs would favor receptor 
clustering. However, it has been shown that neither phloretin, nor 6-ketocholestanol changes the mem-
brane thickness arguing against this model46,47.
6. Since the interaction with lipids affects the conformation of ErbB proteins, changes in the dipole potential 
and consequent alterations in lipid-protein interactions may change the distribution of ErbB receptors 
Figure 6. Correlation between the activation of ErbB2, its raft localization and the dipole potential. 
SKBR-3 cells were pretreated with 6-ketocholestanol (6-KC) to increase the dipole potential. Control cells 
were only incubated with Pluronic F-127. Cells were stimulated with EGF followed by staining all membrane-
localized ErbB2 with trastuzumab, tyrosine phosphorylated ErbB2 (p-ErbB2) with Ab18 and GM1 gangliosides, 
localized in lipid rafts, with subunit B of cholera toxin (CTX). The tyrosine phosphorylation of ErbB2 
normalized to its membrane expression (p-ErbB2/ErbB2) was separately evaluated for image regions showing 
high and low CTX labeling (A). The Pearson correlation coefficient (r) between p-ErbB2 and CTX (B) and 
between total membrane ErbB2 and CTX (C) were calculated. Error bars represent the standard error of the 
mean determined from 25 images recorded in three independent experiments.
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between raft and non-raft domains. The majority of studies found that lipid rafts inhibit ligand binding and 
signaling mediated by ErbB1 and that ErbB1 activation takes place upon concomitant migration of ErbB1 
out of lipid rafts38,48, although alternative views have also been presented35. Our results imply that activa-
tion of ErbB2 by EGF preferentially takes place outside lipid raft domains and an increased dipole potential 
mimics this effect. Therefore, dipole potential-induced redistribution of receptors can also enhance their 
association and signaling.
By one of these mechanisms monomers of ErbB proteins are more prone to dimerization after 
6-ketocholestanol treatment. In this way, more monomers are available to form homo- and heterodimers 
after growth factor stimulation. Therefore, EGF-induced formation of ErbB1-2 heterodimers does not lead to 
decreased homoassociation of ErbB1 or ErbB2 because the dimers are formed from the dimerization-prone pool 
of monomers.
The dipole potential may also have implications for the evolution and treatment of cancer. Tumor cells are 
characterized by an increased density of cholesterol-rich lipid rafts49. Since the dipole potential is higher in lipid 
rafts than in the rest of the membrane33, this phenomenon may activate receptor tyrosine kinases in cancer cells. 
2-hydroxylated unsaturated fatty acids have been shown to decrease the dipole potential and to have beneficial 
effects in the treatment of cancer and inflammatory diseases implying that attenuation of signaling upon lowering 
the dipole potential may even have therapeutic implications50.
In summary, we have shown that the dipole potential exerts significant effects on the ligand binding, cluster-
ing and signaling of ErbB proteins. We suggest that the dipole potential primarily affects receptor dimerization 
mediated by TMDs. This dimerization induced by an elevated dipole potential will bring about TMD-driven 
receptor activation leading to reduced affinity of growth factor binding and increased signaling mediated by 
dimers stabilized by interactions among the extracellular domains and the TMD dimerization motifs stabilizing 
active dimers17. Our observations emphasize that the dipole potential must not be overlooked when interpreting 
the effect of the membrane environment on receptor clustering.
Materials and Methods
Cells, Plasmids and Reagents. SKBR-3, HeLa and A431 cells were obtained from the American Type 
Culture Collection (ATCC, Manassas, VA) and grown according to their specifications. F1-4, a CHO subline 
stably expressing ErbB1-EGFP has been described previously51. Information about which cell line was used 
for the different experiments is available in Supplementary Materials and Methods. For experiments involving 
growth factor stimulation serum-starved cells were incubated with 100 ng/ml (~16 nM) of recombinant human 
EGF (R&D Systems, Minneapolis, MN or Peprotech, London, UK) for 5 min at 37 °C in Tyrode’s buffer with 
10 mM glucose and 0.1% BSA. The pSV2neuNT plasmid coding for the human NeuT protein was a kind gift from 
Richard Pestell (Thomas Jefferson University, Philadelphia, PA)52. Cloning of mYFP-tagged Val659Glu mutant of 
ErbB2 is described in Supplementary Materials and Methods.
Labeling of antibodies and cells. For microscopic experiments, cells were cultured on Lab-Tek II cham-
bered coverglass (Nalge Nunc International, Rochester, NY). For flow cytometry, cells were harvested by trypsin-
ization. Trastuzumab (against ErbB2) and Ab11 (against ErbB1) were purchased from Roche (Basel, Switzerland) 
and Thermo Fisher Scientific (Waltham, MA), respectively. These antibodies were labeled with AlexaFluor546 
and AlexaFluor647 dyes according to the manufacturer’s specifications (Life Technologies/Thermo Fisher 
Scientific, Waltham, MA). Antibodies against phosphotyrosine (PY99, Santa Cruz, Dallas, TX), ErbB2 phos-
phorylated at Tyr1248 (Ab18, Thermo Fisher Scientific) and ErbB1 phosphorylated at Tyr1068 (1H12, Cell 
Signaling Technology, Danvers, MA) were visualized by secondary staining with AlexaFluor546-goat-anti-mouse 
antibodies (Life Technologies/Thermo Fisher Scientific). Tetramethylrhodamine-labeled EGF was purchased 
from LifeTechnologies. Transient transfection of HeLa cells was carried out with an Amaxa Nucleofector device 
(Lonza, Basel, Switzerland). The transfection solution and the program were selected according to the “Cell & 
Transfection Database” of the manufacturer.
Measuring and Altering the Dipole Potential. The dipole potential was measured using a ratio-
metric assay. Cells were incubated with 2 μ M di-8-ANEPPS (4-(2-[6-(dioctylamino)-2-naphthalenyl]ethe-
nyl)-1-(3-sulfopropyl)pyridinium inner salt, Invitrogen, Carlsbad, CA) for 20 min at 4 °C, and their fluorescence 
was measured using a ratiometric assay shown to be responsive to changes in the dipole potential53. The dye 
was excited at 458 and 514 nm, and its emission was measured above 630 nm in order to avoid fluidity-induced 
changes in the excitation ratio54. Image acquisition was performed using an LSM510 confocal laser scanning 
microscope (Carl Zeiss AG, Jena, Germany). Image processing was carried out with the DipImage toolbox (Delft 
University of Technology, Delft, The Netherlands) under Matlab (Mathworks, Natick, MA). Segmentation of 
images into membrane and non-membrane pixels was carried out with the manually seeded watershed algorithm 
using a custom-written Matlab program as described previously55. The fluorescence intensity ratio of the cell 
membrane pixels was calculated after background subtraction. The dipole potential was increased and decreased 
by treating cells with 6-ketocholestanol (3β -hydroxy-5α -cholestan-6-one) (Sigma Aldrich, St. Louis, MO) and 
phloretin (3-(4-hydroxyphenyl)-1-(2,4,6-trihydroxyphenyl)propan-1-one) (Sigma Aldrich, St. Louis, MO), 
respectively at a concentration of 100 μ M for 10 min at room temperature in the presence of 0.05% (v/v) Pluronic 
F-12754.
Determination of the correlation between tyrosine phosphorylation of ErbB2, its raft localiza-
tion and the dipole potential. Control cells and those with an altered dipole potential were treated with 
www.nature.com/scientificreports/
9Scientific RepoRts | 6:35850 | DOI: 10.1038/srep35850
EGF followed by staining with subunit B of cholera toxin (CTX) and antibodies against ErbB2 and tyrosine phos-
phorylated ErbB2. Details of the labeling protocol and image analysis are described in Supplementary Materials 
and Methods.
Determination of the binding affinity of EGF. The dissociation constant characterizing the binding 
affinity of EGF to ErbB1 was determined by competitive and non-competitive binding assays using fluorescently 
labeled EGF. Tetramethylrhodamine-congjutated EGF (TAMRA-EGF, LifeTechnologies) was reconstituted at a 
concentration of 10 μ M. A dilution series was prepared with each vial containing 250 μ l EGF diluted in Tyrode’s 
buffer supplemented with 0.1% (w/v) BSA. The solutions were kept on ice before adding 20 μ l of cold cell sus-
pension containing 100000 cells. Cells were incubated in the presence of TAMRA-EGF for 30 min on ice with 
shaking. The fluorescence intensity of the samples was measured on a FACS Aria III flow cytometer without 
washing to prevent the dissociation of fluorescent EGF from ErbB1. TAMRA was excited at 561 nm, and its emis-
sion was detected through a 595 nm band-pass filter. Analysis of flow cytometric data was carried out with FCS 
Express (Denovo Software, Thornhill, Ontario, Canada). The binding curves were fitted to the Hill equation on 
a logarithmic scale:
= +
−
+ −
I I I I
1 10 (1)n K cmin
max min
(log log )d
where I is the intensity of the sample labeled with fluorescent EGF at a concentration of c, Imin and Imax are the 
minimal and maximal intensities, respectively. Kd and n are the dissociation constant and the Hill coefficient, 
respectively.
Competitive binding curves were measured as described above, but the dilution series contained unlabeled 
EGF mixed with a constant concentration of labeled EGF. The binding curves were fitted to the equation below:
= +
−
+ −
I I I I
1 10 (2)n c ICmin
max min
(log log 50)
where
=
+IC K K
K
50 C
(3)i
d
d
T
Kd and Ki are the dissociation constants of TAMRA-EGF and unlabeled EGF, respectively, and cT is the concen-
tration of TAMRA-EGF.
Flow Cytometric Förster Resonance Energy Transfer (FRET) Measurements. ErbB1 homoassocia-
tion and ErbB2 homoassociation were measured with Ab11 antibody and trastuzumab, respectively. ErbB1-ErbB2 
heteroassociation was measured with AlexaFluor546-Ab11 (against ErbB1) and AlexaFluor647-trastuzumab 
(against ErbB2). The measurements were carried out with a FACS Aria III flow cytometer (BD Biosciences, San 
Jose, CA) according to principles described in Supplementary Materials and Methods.
Number & Brightness Analysis (N&B). An Olympus FV1000 confocal microscope running in pseudo 
photon-counting mode was used to carry out N&B analysis according to Digman et al.56. Cells were kept in 
Tyrode’s buffer with 10 mM glucose and 0.1% BSA during the measurements. mYFP and GFP were excited at 
514 nm and 488 nm, respectively, and their emission was recorded between 530–630 nm and 500–600 nm, respec-
tively. Image series of 100 optical slices adjacent to the coverslip were recorded from live cells to determine the 
variance of the fluorescence intensity. See Supplementary Materials and Methods for additional details of the 
measurement.
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